To evaluate prostate cancer (PCa) detection and incidence of pathologically insignificant PCa (pIPCa) tumour using percent-free PSA (%f-PSA) in patients with total PSA p10 ng ml À1 . From February 2002 to October 2009, 14 453 patients (median 60.5 years) were enrolled in a case-finding protocol for the early diagnosis of PCa. Indications to biopsy were suspicious digital rectal examination; PSA 410 ng ml À1 ; PSAp2.5 ng ml
Introduction
The widespread use of the PSA test along with the introduction of mass screening protocols in Europe 1 and in USA 2 have increased the detection rate of prostate cancer (PCa), which is nowadays the most frequently diagnosed cancer in older men. At the same time, a drop in PCa-related mortality has been reported; 3, 4 recently, the European Randomized Study of Screening for Prostate Cancer (ERSPC) reported a 20% reduction of mortality in the screened arm with an estimated rate of overdiagnosis as high as 50%. 1 Overdiagnosis and the high prevalence of adverse side effects related to unnecessary treatments make the overall benefit of PSA mass screening unclear. Unclear benefits but reliable health-care costs, among them screening is only a small part; Heijnsdijk et al. 5 using MISCAN model to simulate PCa growth and detection in a cohort of 100 000 men (representative of standard European population) over 25 years estimated that the cost of overdetection equals 39% of total costs. Thus, the main concern in early diagnosis of PCa is to reduce the risk of overdiagnosing pathologically insignificant PCa (pIPCa), defined as cancer volume o0.5 ml and a Gleason score (GS)o7 in radical prostatectomy specimens, 6 by using more accurate clinical indications for biopsy as well as nomograms and PSA derivates.
Our aim is to report retrospectively the incidence of pIPCa in a selected population of men with total serum PSA (tPSA) p10 ng ml À1 enrolled in a case-finding protocol for the early diagnosis of PCa, whose preliminary results were published elsewhere. 7 
Materials and methods
The study comprises 14 453 Caucasians patients, aged between 40 and 73 years (median 60.5 years) with a life expectancy 410 years, who were enrolled from February 2002 to October 2009. Most of them-10 329 (71.5%)-were referred to our outpatient Clinic for evaluation of lower urinary tract symptoms. All patients underwent digital rectal examination (DRE), and blood sample was taken for tPSA and percent-free PSA (%f-PSA) assay (Roche Diagnostics, Indianapolis, IN, USA). Patients were divided into three age groups (o50, 50-65 and 465 years). The indications for a prostate biopsy were suspicious DRE, tPSA 410 ng ml À1 , tPSA p2.5 ng ml
À1
with %f-PSAo15%, tPSA between 2.6 and 4 ng ml À1 with %f-PSA o20% and tPSA between 4.1 and 10 ng ml À1 with %f-PSAo25%. 7 Extended prostate needle biopsy was accomplished in all cases under antibiotic prophylaxis in a transperineal way with a tru-cut 18 G needle through a GE Logiq 500 PRO ecograph (General Electric, Milwaukee, WI, USA) supplied with a biplanar transrectal probe (5-6.5 MHz), previous local anaesthesia or under sedation. A median of 18 cores (range [15] [16] [17] [18] [19] [20] [21] [22] and 26 cores (range 20-38) were taken in case of primary 8 and repeated biopsy. 9 Among other biopsy findings, presence of microfocal PCa, defined as a single microfocus (5% or less) of GS p6, was also reported.
In patients diagnosed with PCa, radiotherapy or radical retropubic prostatectomy with bilateral pelvic lymphadenectomy were proposed as curative forms of treatment; in selected cases, an active surveillance protocol was suggested as a conservative management.
Prostatectomy specimens were processed as follows. After inking the specimen, the apical and basal parts were removed by a transversal cut at 4-mm from the distal and proximal margins, respectively. The apical and proximal parts were sectioned parasagittally at 4-mm intervals and perpendicularly to the inked surface. The specimen was step-sectioned at 4-mm intervals perpendicularly to the apical-basal axis of the gland. The presence of extraprostatic extension, seminal vesicle involvement and surgical margin status were recorded. The volume of cancer was reported as the percentage of cancer in the entire specimen according to Bostwick et al.;
10 moreover, incidence of pIPCa was recorded. 6 
Results
The median tPSA was 3.2 ng ml À1 (range: 0.1-645 ng ml
À1
); overall, 6795 (47%), 11 466 (79.3%), 13 782 (95.3%) and 671 (4.7%) patients had a tPSA level p2.5, p4, p10 and 410 ng ml
, respectively. According to our protocol criteria, 2328 patients (16.1%) were eligible for prostate needle biopsy: 205 (8.9%) refused it and 2123 (91.1%) underwent biopsy. Except for 534 men with tPSA 410 ng ml
, 1589 patients (74.8%) submitted to biopsy as primary procedure had a tPSA p10 ng ml
: in 48 (3%), tPSA was p2.5 ng ml
, in 131 (8.2%) and 1410 (88.8%), tPSA was equal to 2.6-4 and 4.1-10 ng ml À1 , respectively. Indication for biopsy was based on PSA values only in 1411 (88.8%) cases, on suspicious DRE in 19 (1.2%) and on PSA values plus DRE in 159 (10%) cases; in the 48, 131 and 1410 patients with tPSA p2.5 ng ml
, included between 2.6-4 and 4.1-10 ng ml
, DRE was abnormal in 20 (45.4%), in 22 (16.7%) and 136 (9.6%) cases, respectively.
PCa was found in 777 out of 2123 (36.6%) biopsies, high grade prostatic intraepithelial neoplasia in 17 (0.8%), atypical small acinar proliferation in 9 (0.4%) and benign histology in 1320 cases (62.2%); 459 out of 777 patients with PCa had a tPSA p10 ng ml À1 and we will refer only to this patient subgroup. According to age groups, PCa was found in 6/550 (1%) cases (o50 years), in 168/9480 (1.7%) cases (50-65 years) and 285/3752 (7.6%) cases (465 years).
Incidence and prevalence of PCa in the population under study are listed in Table 1 ; 311/459 PCa (67.8%) were non-palpable (cT1c) with an higher prevalence in patients with tPSA included between 2.6-4 ng ml À1 (65.4%) and 4.1-10 ng ml À1 (74.5%) in comparison with PSA p2.5 ng ml À1 (28.6%) (P ¼ 0.0001). GS values in patients with PCa and tPSA p10 ng ml À1 are listed in Table 2 .
One hundred-fifty men were submitted to repeated biopsy; in 35 (23.3%) of them a PCa was found: 8 (22.8%), 18 (51.5%) and 9 (25.7%) had tPSA values included between 2.6-4, 4.1-10 and 410 ng ml À1 , respectively. PCa in the 26 patients with tPSA p10 ng ml À1 had a median GS of 6.1 (range: 6-7).
A microscopic neoplastic focus was found in 46 (10%) and in 10 (38.5%) patients with tPSA p10 ng ml À1 , who underwent primary and repeated biopsy, respectively.
Among 459 men with PCa diagnosed by primary biopsy, 40 patients underwent radiotherapy and 419 (91.3%) opted for radical retropubic prostatectomy; no one accepted the active surveillance programme proposed in 67 cases.
On 419 prostatectomy specimens, an organ-confined PCa was found in 244 (58.3%) cases and a locally advanced PCa in the remaining 175 (41.7%) with a median GS equal to 6.4; overall, positive surgical margin, seminal vesicle involvement and positive nodes were found in 115 (27.4%), 26 (6.2%) and 20 (4.7%) cases, respectively (Table 3) .
In the 26 patients with PSA p10 ng ml À1 submitted to radical retropubic prostatectomy after repeated biopsy, 18 (69.2%) had an organ-confined disease (4 pT2aN0; 3 pT2bN0; 11 pT2cN0) and 8 (30.8%) a locally advanced PCa (8 pT3aN0) with a median GS of 6; positive surgical margin were found in two cases (7.7%).
Surgical specimens showed a pIPCa in six (1.4%) and two (7.7%) patients submitted to primary and repeated biopsy, respectively; in details, in 6 (13%) out of 46 cases and 2 (20%) out of 10 men who underwent radical retropubic prostatectomy with a diagnosis of microscopic cancer focus. In six patients, the cancer volume was o0.5 ml and in two cases no tumour at all was found (pT0); median GS was 5.7 (range: 5-6).
Discussion
The aim of any protocol for early detection of PCa should not be to pick up as many cancers as possible, but to Free/total PSA and incidence of insignificant PCa P Pepe and F Aragona detect only those that need to be treated before they become life threatening.
The results of the ERSPC 1 have shown, at a median follow-up of 9 years in men aged 55-69 years at the time of randomization, a 20% reduction of PCa-related mortality with an estimated risk of overdiagnosis/ overtreatment equal to 50% in the screened arm. These figures are exceedingly elevated if compared with screening results for colorectal, breast and cervical cancers.
In PLCO (Prostate Lung Colon Ovarian) screening, 2 after a median follow-up of 7 years, no reduction of PCa mortality was reported, although many bias have been suggested to explain these contradictory results (that is, short follow-up, previous PSA test in all men enrolled in the screening arm). The prevalence of PCa in various protocols for early diagnosis 4, 6, 11 varies in relation to the inclusion criteria (number of biopsy cores, cut-off PSA values for biopsy and so on), but conclusive data on the risk of overdiagnosis have not reported.
Up to now, no imaging modality is able to detect the actual clinical stage of PCa, and a certain number of patients will undergo unnecessary treatments with an high incidence of adverse side effects; alternatively, these men could be enrolled in active surveillance programmes, deferring curative treatment at disease progression (rapid PSA rise, increase of GS or extent of tissue involvement at repeat biopsy) according to patient's age, the coexistence of comorbidities and patient's ability to cope with the psychological stress related to frequent follow-up and to the awareness of the disease.
At present, the main task of screening programmes based on DRE and PSA derivates is improving their accuracy in detecting only significant PCa, as it is probably better to delay a diagnosis of cancer (provided that an opportunity of cure still exists) rather than to diagnose and treat a cancer that will not reduce the patient's life expectancy. It is well known that tPSA values p10 ng ml À1 have a low specificity; especially in men at first observation, %f-PSA has been introduced in clinical practice to improve accuracy reducing the number of biopsy sets and the incidence of indolent cancer. 12 Hoffman et al., 13 proposed a %f-PSA cut-off for biopsy of 25% in men with tPSA 4.0-9.9 ng ml À1 showing a sensitivity equal to 95% in detecting PCa, avoiding 20% of biopsies. Chun et al, 14 on 2323 patients enrolled in a PCa screening programme, reported that half of men with no clinical evidence of cancer had PSA levels o1.0 ng ml À1 and %f-PSA 425%; Capitanio et al, 15 on 3222 patients undergoing PCa screening, reported median tPSA and %f-PSA equal to 1 ng ml À1 and 26%, respectively.
In our case material, the overall incidence of PCa was 5.3%; in particular, 459 (3.3%) out of 13 782 patients with tPSA p10 ng ml À1 had a PCa, that is, 28% of the men submitted to primary biopsy. The relatively high detection rate of cancer in the lowest PSA groups demonstrated the appropriateness of the indications for biopsy: PCa prevalence in case of tPSA p2.5 ng ml
À1
(%f-PSA o15%), 2.6-4 ng ml À1 (%f-PSA o20%) and 4.1-10 ng ml À1 (%f-PSA o25%) was equal to 29.1, 37.4 and 28.8%, respectively. Median GS was 6 in 37% and 46 in 73% of the patients, showing higher values if compared with ERSPC results (GSo6 or equal to 6 in 73 and 37% of the cases, respectively). 1 Moreover, compared with our previous results, 7 we have observed a higher incidence of T1c clinical stage tumours, PCa diagnosed with tPSA p10 ng ml À1 and an increased number of microfocal PCa (59 vs 51.1%, 67.8 vs 51.8%, 1.7 vs 0.9%, respectively), probably because a more extended biopsy protocol was introduced (18 vs 12 cores). 7 Despite most of these patients fulfill D'Amico low-risk criteria, 16 40.3% of 419 men submitted to radical prostatectomy after primary biopsy had a locally advanced disease with positive surgical margin, seminal vesicle involvement and positive nodes in 115 (27.4%), 26 (6.2%) and 20 (4.7%) cases, respectively. Only in 6/419 (1.4%) and 2/26 (7.7%) men submitted to surgery after primary and repeated biopsy, a pIPCa was diagnosed: in details, in six out of eight cases a microfocal cancer was found at biopsy, suggesting that the risk of overdiagnosis was very low in comparison with the estimated 50% risk of ERSPC. 1 Finally, our protocol allowed to spare 757 (25.3%) and 75 (33.3%) biopsies in case of primary and repeated biopsy, respectively, if a PSA cut-off of 4 ng ml À1 for prompting biopsy should be used; moreover, using the same cut-off of 63 out of 459 (13.8%) PCa with PSA p4 ng ml À1 would have been missed. 17 Some limitations of our study deserve mention: first, the majority (71.5%) of men enrolled in our protocol complained of lower urinary tract symptoms introducing a selection bias that can affect the tPSA values and the true incidence of PCa. However, one-third of unselected adult male over 50 years of age suffers from lower urinary tract symptoms, 18 but these symptoms are not associated with an increased risk of PCa; 19 second, tPSA and %f-PSA cut-offs for biopsy have been arbitrary selected on the basis of a literature review. As a consequence; we are able to report only the detection rate for PCa in men submitted to biopsy, not the number of cancer missed in men who did not undergo biopsy according to our inclusion criteria (the true prevalence of PCa in the selected population remains unknown); third, this is a retrospective study. Free/total PSA and incidence of insignificant PCa P Pepe and F Aragona
In conclusion, a PCa detection rate of 28.8% and a risk of detecting pIPCa equal to 1.4% (primary biopsy) and 7.7% (repeated biopsy) in patients with tPSA p10 ng ml À1 should induce to add %f-PSA values in screening programmes to reduce the risk of overdiagnosis; however, an unknown percentage of significant PCa could be missed in men who were excluded from biopsy according to these arbitrary guidelines.
